Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 11/20 | 0.63 |
| ▸ | ACE | P12821 | 10/20 | 0.63 |
| ▸ | CPA1 | P15085 | 1/20 | 0.58 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.58 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.57 |
| ▸ | PSAT1 | Q9Y617 | 1/20 | 0.57 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | PPARA | Q07869 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7507834 | 1.00 | MME (0.63) | MMEACECPA1ACE2SRR | |
| SCHEMBL16948243 | 1.00 | MME (0.63) | MMEACECPA1ACE2SRR | |
| SCHEMBL265577 | 0.88 | CYP1A2 (0.61) | CPA1 | |
| SCHEMBL65930 | 0.88 | CYP1A2 (0.61) | CPA1 | |
| SCHEMBL265135 | 0.88 | CYP1A2 (0.61) | CPA1 | |
| SCHEMBL11237591 | 0.88 | TBXAS1 (0.59) | MMEACE | |
| SCHEMBL12258522 | 0.87 | MME (0.54) | MMEACECPA1ACE2SRR | |
| SCHEMBL12258520 | 0.87 | MME (0.54) | MMEACECPA1ACE2SRR | |
| SCHEMBL12258523 | 0.87 | MME (0.54) | MMEACECPA1ACE2SRR | |
| Water SCHEMBL10936876 | 0.86 | CYP1A2 (0.59) | CPA1SRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | claimed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | claimed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | SEATTLE GENETICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20100256082-A1 | Metallo-hydrolase inhibitors using metal binding moietes in combination with targeting moieties | VIAMET PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2046119-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | Myriad Genetics, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008006099-A2 | TREATMENT OF PSYCHIATRIC DISORDERS | MYRIAD GENETICS, INC. (US) | 2008-01-10 | — | — | WO | disclosed |
| CN-101022810-A | Novel biaromatic compounds which activate peroxisome proliferator activated receptor-like receptors and their use in cosmetic or pharmaceutical compositions | GALDERMA RES & DEV (FR) | 2007-08-22 | — | — | CN | disclosed |
| EP-1077941-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | Novo Nordisk A/S (DK) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058501-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1999-11-18 | — | — | WO | disclosed |
| WO-1993012076-A1 | REAGENTS FOR AUTOMATED SYNTHESIS OF PEPTIDE ANALOGS | CORVAS INTERNATIONAL INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| EP-0360258-A2 | Amino acid quinoline and naphthyridine derivatives | ABBOTT LABORATORIES (US) | 1990-03-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123465-A1 | MONOMETHYLVALINE COMPOUNDS HAVING PHENYLALANINE SIDE-CHAIN MODIFICATIONS AT THE C-TERMINUS | MMAB, PTMS, DNPEP | MME 463/4885ACE 2987/4885CPA1 1805/4885 |
| US-20100256082-A1 | Metallo-hydrolase inhibitors using metal binding moietes in combination with targeting moieties | MMEL1, MPI, METAP1 | MME 42/4885ACE 253/4885CPA1 1284/4885 |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | MME 1/4885ACE 7/4885CPA1 106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.